Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product (Approved, Off-label), By Mechanism Of Action (Peripherally Acting Drugs, Centrally Acting Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
- Report ID: GVR-4-68040-235-6
- Number of Report Pages: 110
- Format: PDF, Horizon Databook
- Historical Range: 2018 - 2022
- Forecast Period: 2024 - 2030
- Industry: Healthcare
Market Segmentation
- Anti-Obesity Medication Product Outlook (Revenue, USD Million, 2018 - 2030)
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Anti-Obesity Medication Mechanism of Action Outlook (Revenue, USD Million, 2018 - 2030)
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Anti-Obesity Medication Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Anti-Obesity Medication Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Others
- Approved
- North America Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- North America Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- U.S.
- U.S. Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- U.S. Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- U.S. Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- U.S. Anti-Obesity Medication Market, By Product
- Canada
- Canada Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Canada Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Canada Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Canada Anti-Obesity Medication Market, By Product
- North America Anti-Obesity Medication Market, By Product
- Europe
- Europe Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Others
- Approved
- Europe Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Europe Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- UK
- UK Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- UK Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- UK Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- UK Anti-Obesity Medication Market, By Product
- Germany
- Germany Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Germany Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Germany Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Germany Anti-Obesity Medication Market, By Product
- Spain
- Spain Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Spain Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Spain Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Spain Anti-Obesity Medication Market, By Product
- France
- France Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- France Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- France Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- France Anti-Obesity Medication Market, By Product
- Italy
- Italy Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Italy Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Italy Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Italy Anti-Obesity Medication Market, By Product
- Denmark
- Denmark Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Denmark Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Denmark Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Denmark Anti-Obesity Medication Market, By Product
- Sweden
- Sweden Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Sweden Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Sweden Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Sweden Anti-Obesity Medication Market, By Product
- Norway
- Norway Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Norway Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Norway Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Norway Anti-Obesity Medication Market, By Product
- Europe Anti-Obesity Medication Market, By Product
- Asia Pacific
- Asia Pacific Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Asia Pacific Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Asia Pacific Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Japan
- Japan Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Japan Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Japan Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Japan Anti-Obesity Medication Market, By Product
- China
- China Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- China Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- China Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- China Anti-Obesity Medication Market, By Product
- India
- India Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- India Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- India Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- India Anti-Obesity Medication Market, By Product
- Australia
- Australia Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Australia Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Australia Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Australia Anti-Obesity Medication Market, By Product
- Thailand
- Thailand Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Thailand Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Thailand Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Thailand Anti-Obesity Medication Market, By Product
- South Korea
- South Korea Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- South Korea Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- South Korea Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- South Korea Anti-Obesity Medication Market, By Product
- Latin America
- Latin America Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Latin America Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Latin America Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Brazil
- Brazil Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- BrazilAnti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- BrazilAnti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Brazil Anti-Obesity Medication Market, By Product
- Mexico
- Mexico Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Mexico Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Mexico Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Mexico Anti-Obesity Medication Market, By Product
- Argentina
- Argentina Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- ArgentinaAnti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- ArgentinaAnti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Argentina Anti-Obesity Medication Market, By Product
- Latin America Anti-Obesity Medication Market, By Product
- MEA
- MEA Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- MEA Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- MEA Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- South Africa
- South Africa Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- South Africa Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- South Africa Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- South Africa Anti-Obesity Medication Market, By Product
- Saudi Arabia
- Saudi Arabia Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Saudi Arabia Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Saudi Arabia Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- Saudi Arabia Anti-Obesity Medication Market, By Product
- UAE
- UAE Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- UAE Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- UAE Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Others
- UAE Anti-Obesity Medication Market, By Product
- Kuwait
- Kuwait Anti-Obesity Medication Market, By Product
- Approved
- Bupropion-naltrexone (Contrave)
- Liraglutide (Orlistat)
- Orlistat
- Xenical
- Alli
- Phentermine-topiramate (Qsymia)
- Semaglutide (Wegovy)
- Setmelanotide (Imcivree)
- Tirzepatide (Zepbound)
- Off Label
- Semaglutide (Xenical Alli)
- Liraglutide (Semaglutide (Wegovy))
- Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity))
- Others
- Approved
- Kuwait Anti-Obesity Medication Market, By Mechanism of Action
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Kuwait Anti-Obesity Medication Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Other
- Kuwait Anti-Obesity Medication Market, By Product
- MEA Anti-Obesity Medication Market, By Product
- Asia Pacific Anti-Obesity Medication Market, By Product
- North America
Report content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- Market size
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2018 to 2030
- Market estimates and forecast for product segments up to 2030
- Regional market size and forecast for product segments up to 2030
- Market estimates and forecast for application segments up to 2030
- Regional market size and forecast for application segments up to 2030
- Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
